{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-004739","form_type":"8-K","ticker":"MIRA","cik":"0001904286","company_name":"MIRA PHARMACEUTICALS, INC.","filed_at":"2026-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.731299+00:00","generated_at":"2026-05-16T05:45:38.939231+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MIRA Pharma initiates final cohort of Ketamir-2 Phase 1 MAD trial; 50 volunteers dosed","bullets":["Phase 1 MAD trial final cohort dosing underway; 50 healthy volunteers dosed, 6 remaining; completion expected by Q1 2026.","Phase 2a proof-of-concept study for CIPN planned; protocol submission to FDA after Phase 1; targeting Q2 2026 start.","Plans to pursue FDA Fast Track designation for Ketamir-2; to present Phase 1 data at AACR April 2026.","Preclinical programs SKNY-1 (weight loss/nicotine addiction) and MIRA-55 (inflammatory pain) advancing toward IND-enabling by year-end 2026.","Engaging in partnering discussions at BIO Partnering Investment & Growth Summit in March 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-004739","json":"https://secwatch.observer/filing/0001493152-26-004739.json","markdown":"https://secwatch.observer/filing/0001493152-26-004739.md","text":"https://secwatch.observer/filing/0001493152-26-004739.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1904286/000149315226004739/0001493152-26-004739-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1904286/000149315226004739/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T05:45:38.939231+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}